Your Name (required)
Your Email (required)
Study of Interest:
Autism (children and adolescents) ADHD Migrane- ACT: Preventative Treatment for Chronic Migraine in Teens Migrane- FORWARD: Open-label Study for Adults with Chronic Migraine Migrane- New Class of Oral Medication for Chronic Migraine Prevention Multiple Sclerosis Redefine: Autoinjectors in patients with RRMS Multiple Sclerosis - Laquinamod for PPMS, Phase 2 Multiple Sclerosis - Aspire: Botox for spasticity Multiple Sclerosis - Oral, extended-release baclofen Opioid Induced Constipation
Currently enrolling for an ADHD study
See if you qualify for our ADHD study.
For children and adolescents
Currently Enrolling: Oral medication for children and adolescents aged 6 to 17 years with Irritability associated with Autistic Disorder.
FORWARD: Open-label Study for Adults with Chronic Migraine
Comparing Preventative Treatment Options for Chronic Migraine: BOTOX® vs. Topiramate
New Class of Oral Medication for Chronic Migraine Prevention
Evaluating the Efficacy and Safety of AMG 334 for Migraine Prevention + (Second phase of study includes a long-term, open-label extension study)
ACT: Preventative Treatment for Chronic Migrane in Teens
A Clinical Trial to Evaluate BOTOX® as a Preventative Treatment for Chronic Migraines in Adolescents.
REDEFINE: Easy-of-Use with Rebif Rebidose and Rebiject Autoinjectors in Patients with RRMS
Clinical Trials Identifier: NCT02019550
Laquinamod for PPMS, Phase 2
A Phase 2 Clinical Study in Subjects With Primary Progressive Multiple Sclerosis to Assess the Efficacy, Safety and Tolerability of Two Oral Doses of Laquinimod Either of 0.6 mg/Day or 1.5mg/Day (Experimental Drug) as Compared to Placebo
ASPIRE: Botox for Spasticity
Clinical Trials Identifier NCT01930786
Oral, Extended-Release Baclofen
Clinical Trials Identifier NCT01457352
Currently Enrolling for an Opioid Induced Constipation study
See if you qualify for our Opioid Induced Constipation study